Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: Two cases
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Tenofovir disoproxil fumarate (TDF) is effective against chronic hepatitis B (CHB) infection and its use is increasing rapidly worldwide. However, it has been established that TDF is associated with renal toxicity in human immunodeficiency virus-infected patients, while severe or symptomatic TDF-associated nephrotoxicity has rarely been reported in patients with CHB. Here we present two patients with TDF-associated nephrotoxicity who were being treated for CHB infection. The first patient was found to have clinical manifestations of proximal renal tubular dysfunction and histopathologic evidence of acute tubular necrosis at 5 months after starting TDF treatment. The second patient developed acute kidney injury at 17 days after commencing TDF, and he was found to have membranoproliferative glomerulonephritis with acute tubular injury. The renal function improved in both patients after discontinuing TDF. We discuss the risk factors for TDF-associated renal toxicity and present recommendations for monitoring renal function during TDF therapy.
Abstract
Tenofovir disoproxil fumarate (TDF) is effective against chronic hepatitis B (CHB) infection and its use is increasing rapidly worldwide. However, it has been established that TDF is associated with renal toxicity in human immunodeficiency virus-infected patients, while severe or symptomatic TDF-associated nephrotoxicity has rarely been reported in patients with CHB. Here we present two patients with TDF-associated nephrotoxicity who were being treated for CHB infection. The first patient was found to have clinical manifestations of proximal renal tubular dysfunction and histopathologic evidence of acute tubular necrosis at 5 months after starting TDF treatment. The second patient developed acute kidney injury at 17 days after commencing TDF, and he was found to have membranoproliferative glomerulonephritis with acute tubular injury. The renal function improved in both patients after discontinuing TDF. We discuss the risk factors for TDF-associated renal toxicity and present recommendations for monitoring renal function during TDF therapy.
참고문헌 (21)
- Gallant JE, "Tenofovir disoproxil fumarate", Clin Infect Dis, 37, pp.944~950 (2003)
- Kearny BP, "Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics", Clin Pharmacokinet, 43, pp.595~612 (2004)
- Yuen MF, "Treatment of chronic hepatitis B: evolution over two decades", J Gastroenterol Hepatol, 26(Suppl 1), pp.138~143 (2011)
- Van Rompay KK, "Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects", Antimicrob Agents Chemother, 52, pp.3144~3160 (2008)
- Verhelst D, "Fanconi syndrome and renal failure induced by tenofovir: a first case report", Am J Kidney Dis, 40, pp.1331~1333 (2002)
- Hall AM, "Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence", Am J Kidney Dis, 57, pp.773~780 (2011)
- Fontana RJ, "Side effects of long-term oral antiviral therapy for hepatitis B", Hepatology, 49(5 Suppl), pp.S185~S195 (2009)
- Pol S, "First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real life’ setting: from clinical trials to clinical practice", J Viral Hepat, 19, pp.377~386 (2012)
- Gracey DM, "Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection", Antivir Ther, 18, pp.945~948 (2013)
- Viganò M, "Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal", J Clin Virol, 61, pp.600~603 (2014)
- Hwang HS, "Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection", Hepatology, 62, pp.1318~1320 (2015)
- Duarte-Rojo A, "Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B", Therap Adv Gastroenterol, 3, pp.107~119 (2010)
- Heathcote EJ, "Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B", Gastroenterology, 140, pp.132~143 (2011)
- Lampertico P, "525 Tenofovir monotherapy for naïve patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months", J Hepatol, 56(Suppl 2), pp.S208~ (2012)
- Mauss S, "Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B", J Hepatol, 55, pp.1235~1240 (2011)
- Fernandez-Fernandez B, "Tenofovir Nephrotoxicity: 2011 Update", AIDS Res Treat, 2011, pp.354908~ (2011)
- Wever K, "Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men", J Acquir Immune Defic Syndr, 55, pp.78~81 (2010)
- Tourret J, "Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?", J Am Soc Nephrol, 24, pp.1519~1527 (2013)
- Gupta SK, "Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America", Clin Infect Dis, 40, pp.1559~1585 (2005)
- European Association For The Study Of The Liver, "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Herlitz LC, "Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities", Kidney Int, 78, pp.1171~1177 (2010)